Derek Ogg PhD

Chief Scientific Officer and Protein Crystallographer

Derek Ogg has over 25 years of experience in the pharmaceutical industry, with expertise in all aspects of structural biology.

Derek Ogg PhD Chief Scientific Officer and Protein Crystallographer

More about Derek Ogg PhD

Born in the Scottish Borders Derek went to university planning become a marine biologist but after discovering he did not like being cold and wet decided on a career that would keep him indoors so studied biochemistry and biophysics instead.

After finishing his Ph.D at Leeds University he moved to Uppsala Sweden to work as a protein crystallographer for a small start-up biotech. Almost 20 years later and much to his surprise he was still in Sweden happily married to a native and with two children and a Volvo. After working at Pharmacia and the Structure Genomics Consortium he returned to the UK where he continues to suffer from the resulting culture shock. He worked for a further 10 years at AstraZeneca before joining Peak Proteins as the CSO.

He still has a Volvo.

Development of Selective Phosphatidylinositol 5-Phosphate 4-Kinase γ Inhibitors with a Non-ATP-competitive, Allosteric Binding Mode
J. Med. Chem. 2022, 65,
Helen K. Boffey, Timothy P. C. Rooney, Henriette M. G. Willems, Simon Edwards, Christopher Green, Tina Howard, Derek Ogg, Tamara Romero, Duncan E. Scott, David Winpenny, James Duce, John Skidmore, Jonathan H. Clarke, and Stephen P. Andrews

Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase Inhibitors
Journal of the American Chemical Society 2020 142 (23), 10358-10372
Kirsten McAulay, Emily A. Hoyt, Morgan Thomas, Marianne Schimpl, Michael S. Bodnarchuk, Hilary J. Lewis, Derek Barratt, Deepa Bhavsar, David M. Robinson, Michael J. Deery, Derek J. Ogg, Gonçalo J. L. Bernardes, Richard A. Ward, Michael J. Waring, and Jason G. Kettle

Heparan sulfates are critical regulators of the inhibitory megakaryocyte-platelet receptor G6b-B
Elife. 2019 8. pii: e46840
Vögtle T, Sharma S, Mori J, Nagy Z, Semeniak D, Scandola C, Geer MJ, Smith CW, Lane J, Pollack S, Lassila R, Jouppila A, Barr AJ, Ogg DJ, Howard TD, McMiken HJ, Warwicker J, Geh C, Rowlinson R, Abbott WM, Eckly A, Schulze H, Wright GJ, Mazharian A, Fütterer K, Rajesh S, Douglas MR, Senis YA.

Discovery of N-{4-[(6,7-dimethoxyquinazolin-4-yl)oxy]phenyl}-2-[4-(propan-2-yl)-1H-1,2,3-triazol-1-yl]acetamide (AZD3229), a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.
J. Med Chem. 2018, 61(19):8797–8810.
Kettle JG, Anjum R, Barry E, Bhavsar D, Brown C, Boyd S, Campbell A, Goldberg K, Grondine M, Guichard S, Hardy CJ, Hunt T, Jones RDO, Li X, Moleva O, Ogg D, Overman RC, Packer MJ, Pearson S, Schimpl M, Shao W, Smith A, Smith JM, Stead D, Stokes S, Tucker M, Ye Y.

Potent and selective bivalent inhibitors of BET bromodomains.
Nat Chem Biol. 2016, 12(12):1097-1104.
Waring MJ, Chen H, Rabow AA, Walker G, Bobby R, Boiko S, Bradbury RH, Callis R, Clark E, Dale I, Daniels DL, Dulak A, Flavell L, Holdgate G, Jowitt TA, Kikhney A, McAlister M, Méndez J, Ogg D, Patel J, Petteruti P, Robb GR, Robers MB, Saif S, Stratton N, Svergun DI, Wang W, Whittaker D, Wilson DM, Yao Y.

Discovery of a novel allosteric inhibitor-binding site in ERK5: comparison with the canonical kinase hinge ATP-binding site.
Acta Crystallogr D Struct Biol. 2016, 72:682-93.
Chen H, Tucker J, Wang X, Gavine PR, Phillips C, Augustin MA, Schreiner P, Steinbacher S, Preston M, Ogg D. 

Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.
Oncotarget. 2016. 7(17):24252-68.
Patani H, Bunney TD, Thiyagarajan N, Norman RA, Ogg D, Breed J, Ashford P, Potterton A, Edwards M, Williams SV, Thomson GS, Pang CS, Knowles MA, Breeze AL, Orengo C, Phillips C, Katan M.

Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods.
J Comput Aided Mol Des. 2015, 29(12):1109-22.
Roos K, Hogner A, Ogg D, Packer MJ, Hansson E, Granberg KL, Evertsson E, Nordqvist A.

Pyrimidinone Nicotinamide Mimetics as Selective Tankyrase and Wnt Pathway Inhibitors Suitable for in Vivo Pharmacology
ACS Medicinal Chemistry Letters, 2015, 6: 254-259
J Johannes, L Almeida; B Barlaam, PA Boriack-Sjodin, R Casella; R Croft, A Dishington, L Gingipalli, CA Gu, J Hawkins, J Holmes, T Howard, J Huang, S Ioannidis, S Kazmirski, M Lamb, T McGuire, J Moore, D Ogg, A Patel, K Pike, T Pontz, G Robb, N Su, H Wang, X Wu, H-J Zhang, Y Zhang, X Zheng, T Wang

Identification and optimisation of 3,3-dimethyl-azetidin-2-ones as potent and selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
Med Chem Commun2014 5:57-63.
McCoull W, Augustin M, Blake C., Ertan A., Kilgour E., Krapp S, Moore JE., Newcombe NJ, Packer M, Rees A, Revill J, Scott JS, Selmi N, Gerhardt S, Ogg DJ, Steinbacher S, Whittamore PR.,

Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy.
Bioorg Med Chem Lett. 201424: 870-9
Kale RR, Kale MG, Waterson D, Raichurkar A, Hameed SP, Manjunatha MR, Kishore Reddy BK, Malolanarasimhan K, Shinde V, Koushik K, Jena LK, Menasinakai S, Humnabadkar V, Madhavapeddi P, Basavarajappa H, Sharma S, Nandishaiah R, Mahesh Kumar KN, Ganguly S, Ahuja V, Gaonkar S, Naveen Kumar CN, Ogg D, Boriack-Sjodin PA, Sambandamurthy VK, de Sousa SM, Ghorpade SR.

Thiazolopyridine Ureas as Novel Antitubercular Agents acting through Inhibition of DNA Gyrase B.
J. Med Chem. 2013, 14: 8834-48.
Kale MG, Raichurkar A, Hameed S, Waterson D, McKinney D, Manjunatha MR, Kranthi U, Koushik K, Jena L, Shinde V, Rudrapatana S, Humnabadkar V, Madhavapeddi P, Basavarajappa H, Ghosh A, Ramya VK,  Guptha S, Sharma S, Vachaspathi P, Kumar KNM, Giridhar J, Reddy J, Panduga V, Ganguly S, Ahuja V, Gaonkar S, Kumar CNN, Ogg DJ, Tucker J, Boriack-Sjodin A, de Sousa SM, Sambandamurthy VK and Ghorpade SR.

Employee Spotlight

CSO, Protein Crystallographer and occasional IT support to the desperate.

Worked at AstraZeneca in the UK for 10 years and before that spent almost 20 years in Sweden working for a number of companies including Phamacia, Biovitrum as well as the Structure Genomics Consortium.

Dorothy Hodgkin – pioneer of structural biology and champion for peace & social justice.

The chance to be part of building a company from the start.

Delivering successful projects to clients.

Deliver successful projects to clients.

Not being able to deliver successful projects to clients.

Spirited Away by Studio Ghibli.   Bright Side of the Road by Van Morrison.

Being in a punk band called “Endless Phlegm”